S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   271.10 (+3.29%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.49%)
BABA   199.99 (+1.80%)
MU   46.54 (+0.37%)
GE   7.02 (-2.90%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   372.28 (+0.05%)
BAC   22.82 (+6.69%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
Log in

NASDAQ:STROSutro Biopharma Stock Price, Forecast & News

$9.62
-0.28 (-2.83 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.44
Now: $9.62
$10.30
50-Day Range
$6.19
MA: $9.63
$11.50
52-Week Range
$6.00
Now: $9.62
$12.75
Volume28,760 shs
Average Volume48,172 shs
Market Capitalization$222.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.59
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Read More
Sutro Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STRO
CUSIPN/A
CIKN/A
Phone650-392-8412

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.74 million
Book Value($8.47) per share

Profitability

Net Income$-55,740,000.00
Net Margins-130.44%

Miscellaneous

Employees141
Market Cap$222.22 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.


Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

How has Sutro Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STRO shares have increased by 18.6% and is now trading at $9.62. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sutro Biopharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sutro Biopharma.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Sutro Biopharma.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma Inc (NASDAQ:STRO) issued its earnings results on Monday, March, 16th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $11.31 million for the quarter, compared to the consensus estimate of $9.33 million. View Sutro Biopharma's earnings history.

What price target have analysts set for STRO?

7 brokers have issued twelve-month target prices for Sutro Biopharma's shares. Their forecasts range from $16.00 to $22.00. On average, they expect Sutro Biopharma's share price to reach $18.60 in the next year. This suggests a possible upside of 93.3% from the stock's current price. View analysts' price targets for Sutro Biopharma.

What are Wall Street analysts saying about Sutro Biopharma stock?

Here are some recent quotes from research analysts about Sutro Biopharma stock:
  • 1. According to Zacks Investment Research, "Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. " (3/19/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Sutro is derived from a 13-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.60, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.3%, and tax rate of 15% beginning in FY 2029. Until clarity on Sutro’s collaboration with Celgene and Merck crystallizes, our $18 price target remains leveraged on the outcome of STRO-002’s safety and efficacy outcome, which represents approximately 67% of our rNPV of $12 per share." (5/7/2019)

Has Sutro Biopharma been receiving favorable news coverage?

News stories about STRO stock have been trending very negative on Tuesday, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sutro Biopharma earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutSutro Biopharma.

Are investors shorting Sutro Biopharma?

Sutro Biopharma saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 68,900 shares, an increase of 53.8% from the February 27th total of 44,800 shares. Based on an average trading volume of 23,800 shares, the short-interest ratio is currently 2.9 days. Approximately 0.8% of the company's stock are sold short. View Sutro Biopharma's Current Options Chain.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Momo (MOMO), Vaxart (VXRT), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Amarin (AMRN) and Fortress Biotech (FBIO).

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the following people:
  • Mr. William J. Newell, CEO & Director (Age 61)
  • Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)
  • Dr. Arturo M. Molina, Chief Medical Officer (Age 60)
  • Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory Board
  • Mr. Edward C. Albini, CFO & Sec. (Age 61)

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $9.62.

How big of a company is Sutro Biopharma?

Sutro Biopharma has a market capitalization of $222.22 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe. View additional information about Sutro Biopharma.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is http://www.sutrobio.com/.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel